Uncategorized

iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays

NEW YORK (GenomeWeb) — iCubate said today that it has formed a joint venture with Wondfo Biotech to commercialize infectious disease molecular diagnostics in China. The joint venture — called Wondfo-iCubate Biotech — will develop assays using iCubate’s amplicon-rescued multiplex PCR (arm-PCR) technology, which the company has said can amplify...

Read more

iCubate® receives the 2019 NAITA Global Trade Award

HUNTSVILLE, AL, April 19, 2019 – The North Alabama International Trade Association announced Thursday that Huntsville molecular diagnostic firm iCubate® received the 2019 NAITA Global Trade Award at NAITA’s 36th Annual World Trade Day Luncheon. With international sales leading the way to increased market opportunities, iCubate® provides rapid, accurate and...

Read more

iCubate® and Wondfo Biotech form joint venture to provide high performance infectious disease molecular diagnostics to China

Huntsville, Ala. – iCubate®, Inc. and Guangzhou Wondfo Biotechnology Co., Ltd. (Wondfo) formed the joint venture company, Guangzhou Wondfo iCubate Biotechnology Co., Ltd (Wondfo-iCubate Biotech). The strategic purpose of Wondfo-iCubate Biotech is to couple iCubate’s technology and portfolio of products with Wondfo’s commercial strength in multiple in vitro diagnostic areas and become...

Read more

iCubate® Presents New Product Information to South Central Association of Clinical Microbiology

Huntsville, Ala. March 21, 2019 – iCubate®, a provider of molecular diagnostic solutions for infectious disease detection, hosted a panel presentation at the South Central Association of Clinical Microbiology (SCACM) meeting in Sandusky, Ohio. The presentation titled, “A Clinical Perspective of the iCubate® Solution for Bloodstream Infection” was led by...

Read more

Bacterial Test Well-Suited for Small, Medium Labs, Study Says

June 29, 2018 – NEW YORK (GenomeWeb) – Researchers from four clinical microbiology laboratories reported this month that the iC-GPC assay developed by Huntsville, Alabama-based iCubate is an accurate and reliable tool for the detection of the five most common gram-positive bacteria responsible for bloodstream infections. Additionally, the test detects the...

Read more

Following First FDA Approval for MDx Platform, iCubate Has Eye on Point-of-Care Market

August 30, 2017 – NEW YORK (GenomeWeb) – Having recently secured US Food and Drug Administration approval for its molecular testing platform and first test, the iC-GPC assay for gram-positive bacteria associated with bloodstream infections and antibiotic resistance markers, iCubate is already planning its next commercial assay. The Huntsville, Alabama-based spinout of the...

Read more

CAD Lays the Groundwork for iCubate’s DNA Testing Devices

September 24, 2018 – iCubate, according to the company’s website, is a molecular diagnostic company with a novel multiplex polymerase chain reaction (mPCR) technology. It is also an integrated platform for infectious disease diagnostics and research applications. The iC-Cassette. (Image courtesy of iCubate.) To shed light on what this all...

Read more

iCubate Receives CE Mark for the iC-GPC Assay™

iCubate Receives CE Mark for the iC-GPC Assay™ for use on the iC-System™ iCubate’s platform and initial assay now available for European clinical laboratory use Huntsville, Ala. August 22, 2017 – iCubate, Inc., an innovative molecular diagnostic device company, announced today that it has received CE Mark for its iCubate...

Read more